axlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusse

  • SATT AxLR
    • SATT AxLR
    • Governance
    • Services for companies
    • Annual reports
  • Assisting you
    • Researchers
      • Call-for-projects
    • Companies
    • Startups
    • Practical guide
  • Technology offerings
    • Invest
      • In our technologies
      • In our startups
    • Technologies
    • Startups
    • AxLR TV
  • Working with AxLR
    • Purchasing & public procurement
    • Join us
    • Our startups are hiring
  • Media
    • News
    • Agenda
    • Press kit
    • Communication kit
  • Contact
English
  • French
✕
  • Home
  • TIX001
SPIMA
16 June 2020
GeniaTer-CMT1A
16 June 2020

TIX001

TIX001

Improvement of the therapeutic index of DNA-damaging agents in oncology

Available technology

Desired partnership(s)

  • Licensing
  • Start-Up

IP

  • Patent

Establishment(s)

  • Université de Montpellier
  • Inserm

Laboratory(ies)

  • The Institute of Neurosciences of Montpellier (INM)

Keywords

  • Prevention of the toxicity of DNA-damaging anti-cancer agents
  • Chemotherapy and radiotherapy
  • Improvement of anti-cancer treatment efficacy

Context

Cisplatin is one of the most widely used anti-cancer drugs. It has severe side effects such as ototoxicity, resulting in irreversible hearing loss and balance disorders, but also kidney or peripheral nervous system toxicities.

Benefits

The research team identified the intracellular pathway involved in cisplatin-induced cytotoxicities. In preclinical models, pharmacological blockage of this pathway not only protects against hearing loss but also improves the effectiveness of cisplatin anti-cancer action. These findings have very promising implications for the improvement of the therapeutic index of cisplatin but more broadly in other chemo/radiotherapeutic therapies in oncology that damage DNA. This improvement in the therapeutic index is defined by the improvement of the toxicity-efficiency ratio, these toxicities can be ototoxicity, nephrotoxicity, neurotoxicity...

Applications

Oncology : patients treated with DNA-damaging agents (cisplatin, chemotherapeutics, radiotherapeutics ...)

AVAILABLE TECHNOLOGY | Prevention of the toxicity of DNA-damaging anti-cancer agents – Chemotherapy and radiotherapy – Improvement of anti-cancer treatment efficacy

Share
0

Related posts

8 September 2021

StabCFTR


En savoir +
6 July 2021

HTLV-1


En savoir +
23 June 2021

GEOSOTECH


En savoir +
© 2022, AxLR - SATT Occitanie Méditerranée. All rights reserved. | Legal terms & Privacy policy
English
  • English
  • French